<SEC-DOCUMENT>0001079973-25-000135.txt : 20250127
<SEC-HEADER>0001079973-25-000135.hdr.sgml : 20250127
<ACCEPTANCE-DATETIME>20250127161508
ACCESSION NUMBER:		0001079973-25-000135
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250127

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Hepion Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001583771
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				462783806
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87637
		FILM NUMBER:		25559200

	BUSINESS ADDRESS:	
		STREET 1:		399 THORNALL STREET
		STREET 2:		FIRST FLOOR
		CITY:			EDISON
		STATE:			NJ
		ZIP:			08837
		BUSINESS PHONE:		732-902-4000

	MAIL ADDRESS:	
		STREET 1:		399 THORNALL STREET
		STREET 2:		FIRST FLOOR
		CITY:			EDISON
		STATE:			NJ
		ZIP:			08837

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ContraVir Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20130806

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			S.H.N. Financial Investments Ltd.
		CENTRAL INDEX KEY:			0001890802
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		3 ARIK EINSTEIN ST.
		STREET 2:		B ENTRANCE
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4610301
		BUSINESS PHONE:		927(0)779800501

	MAIL ADDRESS:	
		STREET 1:		3 ARIK EINSTEIN ST.
		STREET 2:		B ENTRANCE
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4610301
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: S.H.N. Financial Investments Ltd. -->
          <cik>0001890802</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>01/22/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001583771</issuerCik>
        <issuerName>Hepion Pharmaceuticals, Inc.</issuerName>
        <issuerCusip>426897104</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>399 Thornall Street</com:street1>
          <com:street2>First Floor</com:street2>
          <com:city>Edison</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>08837</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>S.H.N. Financial Investments Ltd.</reportingPersonName>
      <citizenshipOrOrganization>L3</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1060883.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>1060883.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1060883.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.99</classPercent>
      <typeOfReportingPerson>FI</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Hepion Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>399 Thornall Street, First Floor, Edison, NJ 08837</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>S.H.N. Financial Investments Ltd.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Herzliya Hills
Arik Einstein 3, Israel, 4610301</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Israel</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>1,060,883

The Reporting Person owned 231,849 shares of Common Stock and participated in an offering in which it purchased 829,034 shares of Common Stock, 4,709,428 Pre-Funded Warrants, 5,538,462 Series A Warrants and 5,538,462 Series B Warrants. The amounts in Row (5), (7) and (9) represent 1,060,883 shares of the Issuer's Common Stock. The amounts do not include 4,709,428 Pre-Funded Warrants, 5,538,462 Series A Warrants and 5,538,462 Series B Warrants, which were each subject to a 9.99% beneficial ownership limitation. The percentage set forth on Row (11) of the cover page for the reporting person is based on 10,619,458 shares of Common Stock outstanding (assuming no exercise of Pre-Funded Warrants nor Series A and Series B Warrants being offered in the offering) immediately after the offering based upon the Issuer's Prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission on January 23, 2025.

Nir Shamir is the Chief Executive Officer of SHN. As such, SHN and Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein. To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities for all other purposes.</amountBeneficiallyOwned>
        <classPercent>9.99</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>1,060,883</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>1,060,883</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>S.H.N. Financial Investments Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nir Shamir</signature>
        <title>Nir Shamir, Chief Executive Officer</title>
        <date>01/27/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
